Disclosure of interest: Yi-Hsiang Chen: nothing to disclose, Yi-Chia Wei: nothing to disclose, Wen-Yi Huang: nothing to disclose, Meng Lee: nothing to disclose Poster Session I - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P054 - ESOC25-2304 IMPACT OF DAWN TRIAL ON ENDOVASCULAR THROMBECTOMY : CRCS-K (CLINICAL RESEARCH COLLABORATION FOR STROKE IN KOREA) REGISTRY Yong-Jin Cho 1 , Jong-Moo Park 2 , Kyungbok Lee 3 , Ji Sung Lee 4 , Tai Hwan Park 5 , Keun-Sik Hong 1 , Hong-Kyun Park 1 , Kyusik Kang 6 , Jae-Kwan Cha 7 , Soo Joo Lee 8 , Jun Lee 9 , Mi-Sun Oh 10 , Juneyoung Lee 11 , Beom Joon Kim 12 , Hee-Joon Bae 12 1 Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, South Korea, 2 Department of Neurology, Uijeongbu Eulji Medical center, Eulji University, Uijenongbu, South Korea, 3 Department of Neurology, Soonchunhyang University Seoul Hospital, Seoul, South Korea, 4 Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 5 Department of Neurology, Seoul Medical Center, Seoul, South Korea, 6 Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, 7 Department of Neurology, Dong-A University Hospital, Busan, South Korea, 8 Department of Neurology, Eulji University, School of Medicine, Daejeon Eulji Medical Center, Daejeon, South Korea, 9 Department of Neurology, Yeungnam University Medical Center, Daegu, South Korea, 10 Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, South Korea, 11 Department of Biostatistics, Korea University, Seoul, South Korea, 12 Department of Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea Background and Aims: The aim of this study was to evaluate the impact of DAWN trial on endovascular thrombectomy (EVT) rate in patients with acute ischemic stroke over 6 hours from symptom onset
Gastroenterology 156 , S1236S1237 (2019)
Rated 5/5 by 1 verified customer 50MG Ships Today if ordered within 25 min 25 sec
In 2017, the first CD38-targeting sdAbs were developed by the group of Koch-Nolte, who identified 22 different CD38-specific sdAb families capable of recognizing the three different epitopes (E1, E2, E3) of CD38
